Search PubMed⌕ Search

Biomedical subjects

F Deinhardt

Publications and source records attributed to F Deinhardt.

At least 91 records · Page 5Linked to original sources
PubMed1988

[Antibodies against HTLV I in T-lymphoproliferative diseases of the skin].

The possibility that lymphoproliferative diseases may have a viral etiology has been discussed for many years. The first piece of evidence - in combination with convincing epidemiological data - was the detection of a virus of the HTLV group (HTLV I, ATLV) in patients with adult T-cell leukemia in Japan. There have been no comparable observations made in Europe. In 7 of 72 sera of patients with T-lymphoproliferative diseases in Central Europe, we were able to detect antibodies against HTLV I (ELISA and immunoblot), which might be an indication that retroviruses play a role in the etiology of these diseases.

Adult↗
PubMed1987

[Incidence of parvovirus B19 infection. Seroepidemiologic studies].

Anti-B19-IgG antibodies were tested for by the ELISA method in 768 sera, 76 from children and juveniles, aged 1-15 years, attending the Outpatients Department of the Children's Clinic, University of Munich, and 692 from persons, aged 18-68 years, attending the blood donor service of the Bavarian Red Cross in Munich. 38.4% of sera were positive, with a significant difference between men and women (32.5% vs. 47.5%, P less than or equal to 0.01). A fresh B19 infection was present in 42 subjects by demonstrating anti-B19-IgM in the ELISA test. The sera came from seven patients with infectious erythema, 26 with skin rash of uncertain cause, two with erythroblastosis fetalis, two with enteritis, one with transitory anaemia, one with juvenile polyarthritis, one with lymphadenitis and arthralgia, and two with an asymptomatic course. Viral B19-DNA was demonstrated by nucleic acid hybridization in a blood unit from an asymptomatic blood donor and in amniotic fluid in a case of erythroblastosis fetalis.

Adolescent↗
PubMed1987

Inactivation of HIV in plasma derivatives by beta-propiolactone and UV irradiation.

The inactivation of HIV in human plasma and plasma derivatives by combined treatment with beta-propiolactone and UV-irradiation was investigated. beta-propiolactone inactivated greater than or equal to 3.5 log10 and UV greater than or equal to 2.8 log10 HIV in plasma and beta-propiolactone greater than or equal to 3.5 log10 in cryoprecipitate and UV irradiation greater than or equal to 4.5 log10 in factor VIII concentrate.

Drug Contamination↗
PubMed1987

Sensitivity and specificity of commercial ELISA kits for screening anti-LAV/HTLV III.

Two panels consisting of 236 and 258 anti-LAV/HTLV III positive and 64 and 50 negative sera, respectively (determined in Western blots), were tested with 8 different, commercially available ELISA test kits for detecting LAV/HTLV III antibodies (Abbott, Dupont, Electro-Nucleonics, Litton, Organon, Pasteur, Sorin, Wellcome). Positive sera were selected for levels of antibodies ranging from average to very high, and the negative sera included both negative sera and sera with antibodies to cellular components such as HLA antigens or nuclear membranes. In examination of the 2 panels, the sensitivity of the tests ranged from 97.2 to 100%, and the specificity from 70.0 to 100%. No test was ideal.

Antibodies, Viral↗
PubMed1987

The entire nucleotide sequence of the genome of human hepatitis A virus (isolate MBB).

Hepatitis A virus (HAV) is an important human pathogen causing hepatitis, with high incidence in developed as well as in developing countries. No vaccines are available. In order to determine the primary structure of the HAV genome, we have prepared cDNAs from viral RNA and cloned these into plasmid pBR322. These clones were used to determine the entire nucleotide sequence of the HAV RNA by rapid sequencing methods. We have compared this sequence of 7470 bases to known partial sequences, and one complete sequence of HAV RNA which were obtained recently from different strains of HAV. It is hoped that a comparison of sequence data from different isolates will help in the elucidation of the unusual growth pattern of HAV. In addition, it might provide helpful information about the immunological determinants that elicit the antibody response to infection.

Amino Acid Sequence↗
PubMed1987

Anti-HBc IgM in cases of hepatocellular carcinoma and cirrhosis in Taiwan.

The sera of apparently healthy carriers of hepatitis B virus surface antigen enrolled in the Taiwan Prospective Study were tested retrospectively for anti-HBc IgM, to determine whether this test would be useful in predicting the development of hepatocellular carcinoma (HCC) and/or cirrhosis. In comparison with men who did not develop HCC or cirrhosis, the relative risk of those with anti-HBc IgM elevations was 3.4 and 5.6, respectively. Each of these factors was highly statistically significant, although the difference between them was not. Demonstration of anti-HBc IgM titers of greater than 1:1000 in serum probably reflects ongoing low level viral replication but not recent infection. Anti-HBc IgM appears to be a useful prognostic indicator for the future development of HCC and/or cirrhosis.

Adult↗
PubMed1987

Expression of hepatitis A virus cDNA in Escherichia coli: antigenic VP1 recombinant protein.

The genome of hepatitis A virus (HAV) was reverse transcribed into cDNA and molecularly cloned. cDNA clones coding for the capsid protein VP1 that carries the major HAV antigen were cloned into the expression vector pUR290 and expressed in Escherichia coli. The recombinant fusion protein reacted in an immunoblot with rabbit anti-HAV serum, suggesting that it possesses HAV antigenicity.

Antigens, Viral↗
PubMed1986

Correlation of antibodies to LAV/HTLV III in hemophiliacs with the use of virus-inactivated clotting factors.

The retrovirus LAV/HTLV III, highly likely to be responsible for the acquired immunodeficiency syndrome (AIDS) in some recipients of blood products, can be inactivated by chemical and/or heat treatment, so the use of virus-inactivated factor VIII and factor IX preparations for treating hemophilia A and B has become important. We examined hemophilic children and found that those children treated since 1979 with virus-inactivated preparations did not develop antibodies against LAV/HTLV III. In contrast, 77% of patients treated with conventional factor VIII or factor IX preparations had antibodies against this virus.

Alanine Transaminase↗
PubMed1986

[Increase in the prevalence of antibodies against LAV/HTLV III in drug addicts in West Germany].

Sera obtained from 927 drug addicts in 1983 to 1985 were tested for antibodies against LAV/HTLV-III. There was a steadily rising proportion of positive results: 10.1% in 1983, 17.6% in 1984 and 23.9% in 1985. In each year the prevalence of anti-LAV/HTLV-III was higher among female than male addicts. No increased proportion of positive results was demonstrable in relation to age. Among 152 sera from 1983/84, hepatitis-B markers were found in 72 (43.7%), of whom 10 (14%) were also anti-LAV/HTLV-III positive. Among hepatitis-B marker-negative sera there were 8 (6%) which were also anti-LAV/HTLV-III positive. The prevalence of anti-LAV/HTLV-III in drug addicts in prisons, rehabilitation centres, hospitals and medical practices was similar. There is a danger that prostitution by addicts for obtaining drugs will cause a penetration of LAV/HTLV-III in the rest of the population.

Adult↗
PubMed1986

[HTLV-III in persons with intravenous drug abuse. Correlation of antibodies against HTLV-III with neopterin and TH/TS].

Antibodies against HTLV-III, neopterin levels in blood and urine, TH/TS ratio and hepatitis marker were determined in 34 clinically symptom-free persons known to be intravenous drug abusers. 15 persons were positive in the ELISA and Western-blot tests. There was a strong reaction to protein p24 compared with that to protein p41. In 12 of 14 persons who were antibody-positive the neopterin level in morning urine was elevated; an abnormal TH/TS ratio was present in nine of 13 persons. In future, determination of neopterin and of antibodies against certain proteins of HTLV-III may make it possible to provide a simple way of prognosticating on the course of an HTLV-III infection.

Acquired Immunodeficiency Syndrome↗
PubMed1986

Different immune responses after intradermal and intramuscular administration of vaccine against tick-borne encephalitis virus.

A single multisite intradermal (ID) administration of the same dose used for regular intramuscular (IM) immunisation with vaccine against tick-borne encephalitis virus (TBEV) resulted in seroconversion of all vaccinees within three weeks: with the regular IM schedule, two vaccinations were necessary for all vaccinees to seroconvert. After the first ID vaccination, antibodies of the IgM class against TBEV (anti-TBEV-IgM) were observed in all vaccinees; after the first IM vaccination, only three out of nine vaccinees showed an IgM response. The geometric mean titer (GMT) of anti-TBEV-IgM in seropositives was 5-20-fold higher in the ID group and similar to that after natural infection. The GMT of antibodies of the IgG class against TBEV (anti-TBEV-IgG) was also higher in the ID group but with a less marked difference. Hemagglutination-inhibiting (HI) antibodies appeared earlier and persisted longer after one or two ID injections; after a third vaccination, HI antibody levels were similar in both groups. Side effects after ID vaccination were limited to local reactions. These results indicate that follow-up injections may be omitted or at least reduced after ID administration of the vaccine dose usually used for IM vaccination schedules. However, additional studies in larger groups of vaccinees are necessary before ID vaccination can be recommended for general use.

Adult↗